Physician profile
Michael A Venditto
NPI 1891797759
$1,298.45
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $704 · 2020: $253 · 2021: $214 · 2022: $128.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $616.61 | 2019-2021 | |
| Glaxosmithkline, LLC. | $376.70 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $75.22 | 2019 | |
| Mylan Specialty L.P. | $71.75 | 2019 | |
| Insmed, INC. | $37.08 | 2020 | |
| Genentech USA, INC. | $29.89 | 2019 | |
| Grifols USA, LLC | $23.85 | 2020 | |
| Amarin Pharma, INC. | $22.28 | 2019 | |
| Resmed Corp | $18.52 | 2019 | |
| Circassia INC. | $14.65 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.90 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Venditto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.